Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune® (NovoTTF-100A) – Novocure’s Tumor Treating Fields (TTFields) delivery system …

Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. Mr. Doyle’s presentation will begin at 2 p.m. PST and will …

Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer

Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) presented data on Dec. 12, 2016, from its phase 2 pilot INNOVATE clinical trial at its research and development day suggesting that Tumor Treating Fields (TTFields) in combination with …

Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer

Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) presented data on Dec. 12, 2016, from its phase 2 pilot PANOVA clinical trial at its research and development day …

Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016

Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today the agenda for the company’s research and development day for analysts and investors, which will begin at 1 p.m. EST on Monday, Dec. 12, 2016, in New York City. The event …